Foresight Acquisition Corp. 8-K Summary
Reporting period and context: This Current Report was signed November 22, 2021, with an earliest reported event date of November 18, 2021. Foresight Acquisition Corp. reported developments concerning its proposed business combination with P3 Health Group Holdings, LLC, the predecessor to P3 Health Partners Inc. The filing is primarily transactional and does not provide operating results for P3.
Transaction and Financial Details
- Investors representing approximately $203.7 million of the approximately $208.7 million PIPE commitment agreed to extend the merger-closing deadline from November 25, 2021 to December 8, 2021.
- The merger agreement was amended to extend the required closing date to December 8, 2021. Other material terms were unchanged.
- As of November 16, approximately 27.6 million shares, or approximately 87% of eligible shares, had been submitted for redemption, representing an aggregate redemption price of approximately $276 million.
- As of November 19, holders had submitted net revocations for approximately 7.9 million shares. Final redemptions remained subject to change because the redemption period was extended.
- P3’s board of managers reduced the minimum required Available Cash condition from $400 million to $200 million, based on the redemption level.
- The reduction was stated not to affect the planned addition of $180 million of cash to the post-combination company’s balance sheet.
- The filing does not provide revenue, profit, cash-flow, margin, debt, or liquidity metrics for P3’s operating business.
Stockholder Vote and Material Changes
- At the November 18 special meeting, holders of 27,137,230 shares were represented, equal to 67.2% of voting power and sufficient for a quorum.
- Stockholders approved a proposal to adjourn the meeting to permit additional proxy solicitation and voting.
- Voting results were 24,792,172 for, 2,290,958 against, and 54,100 abstentions.
- The meeting was adjourned to November 24, 2021. Foresight intended to further adjourn it to December 3, 2021.
- Foresight expected to file a proxy supplement on or about November 29, 2021, including revised unaudited pro forma financial statements.
- The revised pro forma statements were expected to reflect accounting for the combination as an acquisition-method business combination rather than a reverse recapitalization. The filing stated that this change would not affect the historical financial statements included in the proxy statement.
Outlook, Risks, and Contingencies
- Completion of the transaction remained contingent on satisfying the amended merger agreement, including the Available Cash condition and other closing requirements.
- Stockholders could change their redemption elections until 5:00 p.m. Eastern Time on December 1, 2021.
- Continued redemptions could affect the transaction’s cash resources and the final ownership and capitalization of the combined company.
- The filing does not state that the transaction had closed as of the reporting date.
Important Investor Verification Points
- Verify the final number of redeemed and revoked shares and the resulting cash available at closing.
- Confirm whether the amended $200 million Available Cash condition was satisfied.
- Review the proxy supplement and revised acquisition-method pro forma financial statements.
- Confirm the final PIPE funding amount and whether all subscription agreements remained in effect.
- Verify the actual closing date, transaction consideration, post-combination capitalization, and the planned $180 million cash addition.